Page 1330 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

References 5

retrospective analysis of prognostic factors influencing survival. 139. Kim SH, Kwak MH, Park S, et al. Clinical characteristics of
Ann Surg Oncol. November 2008;15(11):3268-3271. malignant pericardial effusion associated with recurrence and
133. Gornik HL, Gerhard-Herman M, Beckman JA. Abnormal survival. Cancer Res Treat. December 2010;42(4):210-216.
cytology predicts poor prognosis in cancer patients with peri- 140. McDonald JM, Meyers BF, Guthrie TJ, Battafarano RJ, Cooper
cardial effusion. J Clin Oncol. August 1, 2005;23(22):5211-5216. JD, Patterson GA. Comparison of open subxiphoid pericar-
134. Dosios T, Theakos N, Angouras D, Asimacopoulos P. Risk dial drainage with percutaneous catheter drainage for symp-
factors affecting the survival of patients with pericardial effu- tomatic pericardial effusion. Ann Thorac Surg. September
sion submitted to subxiphoid pericardiostomy. Chest. July 2003;76(3):811-815; discussion 816.
2003;124(1):242-246. 141. Kaira K, Takise A, Kobayashi G, et al. Management of malignant
135. Wagner PL, McAleer E, Stillwell E, et al. Pericardial effusions in pericardial effusion with instillation of mitomycin C in non-small
the cancer population: prognostic factors after pericardial win- cell lung cancer. Jpn J Clin Oncol. February 2005;35(2):57-60.
dow and the impact of paradoxical hemodynamic instability. J 142. Kunitoh H, Tamura T, Shibata T, et al. A randomised trial
Thorac Cardiovasc Surg. January 2011;141(1):34-38. of intrapericardial bleomycin for malignant pericardial effu-
136. Tsang TS, Enriquez-Sarano M, Freeman WK, et al. Consecutive sion with lung cancer (JCOG9811). Br J Cancer. February 10,
1127 therapeutic echocardiographically guided pericardiocen- 2009;100(3):464-469.
teses: clinical profile, practice patterns, and outcomes spanning 143. Maruyama R, Yokoyama H, Seto T, et al. Catheter drainage
21 years. Mayo Clin Proc. May 2002;77(5):429-436. followed by the instillation of bleomycin to manage malignant
137. Jacob S, Sebastian JC, Cherian PK, Abraham A, John SK. pericardial effusion in non-small cell lung cancer: a multi-
Pericardial effusion impending tamponade: a look beyond institutional phase II trial. J Thorac Oncol. January 2007;
Beck’s triad. Am J Emerg Med. February 2009;27(2):216-219. 2(1):65-68.
138. Eisenberg MJ, de Romeral LM, Heidenreich PA, Schiller NB, 144. Moriya T, Takiguchi Y, Tabeta H, et al. Controlling malignant
Evans GT Jr. The diagnosis of pericardial effusion and cardiac pericardial effusion by intrapericardial carboplatin administration
tamponade by 12-lead ECG. A technology assessment. Chest. in patients with primary non-small-cell lung cancer. Br J Cancer.
August 1996;110(2):318-324. October 2000;83(7):858-862.

Section07-O-ref.indd 5 1/21/2015 11:26:51 AM